COMPLETEDNA

PG Versus TG for Advanced PGC

Proximal Versus Total Gastrectomy for Advanced Proximal Gastric Cancer: A Retrospective Double-Center Propensity Score-Matched Cohort Study

NCT06614439•National Taiwan University Hospital

View on ClinicalTrials.gov

Summary

We conducted a retrospective study on patients with pathological stage II-III PGC who underwent PG or TG from 2013 to 2023. Propensity score-matching was applied to adjust for tumor size and stage between the PG and TG groups at a 1:1 ratio. We evaluated the procedural safety, oncological, and functional outcomes.

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Proximal gastric adenocarcinoma after total or proximal gastrectomy.

Exclusion Criteria

•Non-curative resections
•Non-adenocarcinoma histology
•Distally located tumors or middle/proximally located tumors for which distal margin could not be secured by PG
•Remnant gastric cancer
•Clinically T1N0 tumors smaller than 3 cm for which PG was clearly indicated

Locations (1)

National Taiwan University Hospital Hsin-Chu Branch

Hsin-Chu County, Taiwan

Key Dates

Start Date

September 4, 2024

Primary Completion Date

August 1, 2025

Completion Date

September 1, 2025

Last Updated

November 18, 2025

Enrollment

96

ACTUAL participants

Conditions

Gastric AdenocarcinomaGastrectomy

Interventions

proximal gastrectomy

PROCEDURE

total gastrectomy

PROCEDURE

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or Cancer+2 more

View study

RECRUITINGPHASE3

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

NCT05677490

Advanced Esophageal AdenocarcinomaAdvanced Gastric Adenocarcinoma+13 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 18, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITINGPHASE2